biopharma-reporter1d
Spyre Therapeutics launches Phase 1 trials for its extended half-life IBD therapy
The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...
biopharma-reporter1d
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
biopharma-reporter2d
Eisai and Biogen launch Alzheimer’s treatment in South Korea
Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...
biopharma-reporter6d
Amgen announces positive Phase 2 results for its GLP-1-GIP weight loss drug
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
biopharma-reporter6d
Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion
The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...
biopharma-reporter8d
BridgeBio wins FDA approval for inherited cardiomyopathy treatment
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
biopharma-reporter8d
We’ve upgraded BioPharmaReporter to give you more of what you love
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
biopharma-reporter8d
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
biopharma-reporter13d
Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...